Invivyd Logo
About
Mission
Leadership Team
Board of Directors
Partnerships
Platform
Overview
Scientific Publications
Pipeline
Overview
COVID-19
Influenza
Clinical Trials
Product
Investors & Media
Overview
Press Releases
Events & Presentations
Analyst Coverage
Stock Information
Financials & Filings
Corporate Governance
Scientific Publications
Resources
Careers
Our Culture & Values
Open Positions
Contact Us
Boldl
y
HARNESSING A NOVEL APPROACH
Scientific publications
<
Preliminary results for solid organ transplant patients enrolled in CANOPY, a phase 3 study to evaluate efficacy and safety of VYD222, an IgG1 monoclonal antibody for prevention of COVID-19.
Popejoy et al.
ATC
. 2024.
A phase 3 study to evaluate efficacy and safety of VYD222, an IgG1 monoclonal antibody for prevention of COVID-19 (CANOPY): Subset analysis of participants with significant immune compromise in the setting of solid tumor or hematologic malignancies.
Popejoy et al.
ASCO
. 2024.
Population pharmacokinetics of pemivibart (VYD222), an extended–half-life monoclonal antibody in development for the pre-exposure prophylaxis of COVID-19
Rubino et al.
MAD-ID
. 2024.
Six-month interim analysis from a phase 1 first-in-human study of pemivibart: an extended half-life monoclonal antibody (mAb) authorized for pre-exposure prophylaxis for COVID-19 in certain adults and adolescents with moderate to severe immune compromise.
Mahoney et al.
MAD-ID
. 2024.
In vitro
neutralisation of pemivibart (VYD222) against Omicron sublineages.
West et al.
ECCMID
. 2024.
Preliminary safety results from a phase 1 first in human study of VYD222: an extended half-life monoclonal antibody (mAb) in development for COVID-19 prevention.
Mahoney et al.
IDWeek
. 2023.
Prevention of COVID-19 following a single intramuscular administration of adintrevimab: results from a phase 2/3 randomized, double-blind, placebo-controlled trial (EVADE).
Ison et al.
Open Forum Infectious Diseases.
2023.
Efficacy and safety of adintrevimab (ADG20) for the treatment of high-risk ambulatory patients with mild or moderate COVID-19: results from a phase 2/3, randomized, placebo-controlled trial (STAMP) conducted during Delta predominance and early emergence of Omicron.
Ison et al.
Open Forum Infectious Diseases.
2023.
Assessment of effect of adintrevimab on COVID-19 vaccine response.
Tosh et al.
ISIRV-AVG.
2023.
NVD200 potently neutralizes Omicron and its sublineages.
West et al.
ECCMID.
2023.
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers.
Schmidt et al.
Science Translational Medicine.
2023.
ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19, demonstrated broad in vitro neutralisation against SARS-CoV-2 variants.
Kaku et al.
ECCMID.
2022.
Population pharmacokinetics of ADG20, an extended–half-life monoclonal antibody being developed for the treatment and prevention of COVID-19.
Rubino et al.
ECCMID.
2022.
Results from the phase 2/3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of adintrevimab (ADG20) in the treatment of ambulatory participants with mild or moderate COVID-19 (STAMP).
Popejoy et al.
ASM Microbe.
2022.
More
Older publications
Broad and potent in vitro neutralization of SARS-CoV-2 variants by ADG20, a half-life–extended monoclonal antibody in development for the prevention and treatment of COVID-19.
Kaku et al.
ISIRV-WHO.
2021.
Evaluating the safety, tolerability, and pharmacokinetics of ADG20, a half-life–extended monoclonal antibody (mAb) in development for the prevention and treatment of COVID-19: a preliminary analysis of a randomized phase 1 study.
Schmidt et al.
ISIRV-WHO.
2021.
A whole-body quantitative system pharmacology physiologically based pharmacokinetic model that a priori predicts pharmacokinetics of ADG20: an extended half-life monoclonal antibody being developed for the treatment and prevention of COVID-19.
Van Wart et al.
ID Week.
2021.
A whole-body quantitative system pharmacology physiologically based pharmacokinetic model to support dose selection of ADG20: an extended half-life monoclonal antibody being developed for the treatment of coronavirus disease (COVID-19).
Tarbell et al.
ID Week.
2021.
Use of a whole-body quantitative system pharmacology physiologically based pharmacokinetic model to support ADG20 dose selection for the prevention of coronavirus disease (COVID-19).
Van Wart et al.
ID Week.
2021.
Preliminary results from a phase 1 single ascending-dose study assessing safety, pharmacokinetic profile, and serum viral neutralizing antibody titers of ADG20: an extended half-life monoclonal antibody being developed for the treatment and prevention of COVID-19.
Paguntalan et al.
ID Week.
2021.
The ADG20 human monoclonal antibody binds with high affinity and neutralises a wide range of SARS-CoV-2 variants and zoonotic Sarbecoviruses.
Kaku et al.
ECCMID.
2021.
Prophylactic administration of the monoclonal antibody ADG20 provides potent protection against SARS-CoV-2 in rodent and non-human primate models of COVID-19.
Narayan et al.
ECCMID.
2021.
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.
Rappazzo et al.
Science.
2021.
An engineered antibody with broad protective efficacy in murine models of SARS and COVID-19.
Rappazzo et al.
bioRxiv.
2020.
Broad neutralization of SARS-related antibodies by human monoclonal antibodies.
Wec et al.
Science.
2020.
